Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + mitoxantrone
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy regimen consisting of docetaxel and mitoxantrone, primarily studied in sequential rather than simultaneous administration for hormone-refractory prostate cancer (HRPC). Docetaxel is a taxoid that has demonstrated superior survival outcomes compared to mitoxantrone when used as first-line therapy. When used sequentially, patients receiving docetaxel first-line followed by mitoxantrone showed better survival outcomes than the reverse sequence.
- Other names
- mitoxantrone hydrochloridedocetaxel
02
Targets
DNATOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + mitoxantrone.